PMV Pharmaceuticals, Inc.
PMVP
$1.38
$0.042.61%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.12% | -10.53% | -36.49% | -12.73% | -19.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.47% | -11.80% | 3.75% | 2.90% | 13.43% |
| Operating Income | 17.47% | 11.80% | -3.75% | -2.90% | -13.43% |
| Income Before Tax | 14.72% | 8.12% | 21.69% | -9.99% | -21.97% |
| Income Tax Expenses | -40.00% | -- | -- | -108.11% | 100.03% |
| Earnings from Continuing Operations | 14.73% | -3.45% | 21.58% | -9.53% | -1,648.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.73% | -3.45% | 21.58% | -9.53% | -1,648.56% |
| EBIT | 17.47% | 11.80% | -3.75% | -2.90% | -13.43% |
| EBITDA | 17.46% | 11.81% | -3.79% | -4.53% | -15.40% |
| EPS Basic | 16.92% | -0.77% | 23.63% | -6.60% | -1,627.97% |
| Normalized Basic EPS | 16.92% | 10.50% | -7.09% | -7.02% | -20.70% |
| EPS Diluted | 16.92% | -0.77% | 23.63% | -6.60% | -1,627.97% |
| Normalized Diluted EPS | 16.92% | 10.50% | -7.09% | -7.02% | -20.70% |
| Average Basic Shares Outstanding | 2.65% | 2.66% | 2.67% | 2.75% | 1.03% |
| Average Diluted Shares Outstanding | 2.65% | 2.66% | 2.67% | 2.75% | 1.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |